الفهرس 
Title pageOnly 14 pages are availabe for public view
 |  | from | 93 |  |  |
| | | from | 93 | | |
Abstract
Worldwide, prostate cancer (PCa) is the second most commonly diagnosed cancer after lung cancer and the fifth leading cause of cancer death among men. So, identifying new biomarkers for early diagnosis, progression markers and target therapy is a critical need.
CD10 is a cell surface enzyme that is overexpressed in many tumors as in melanomas, papillary thyroid cancer, head and neck squamous cell carcinoma and ovarian carcinoma while its expression decreases in other tumors as in cervical, gastric and colonic adenocarcinoma.
The aim of this work is to study the expression of CD10 in various prostatic adenocarcinoma Gleason’s grades to evaluate the prognostic potential of CD10.
CD10 immunohistochemical expression was studied by using ninety cases of prostatic specimen divided into two groups as follows, group I: 30 cases of benign prostatic hyperplasia (BPH) and group II: 60 cases of prostatic adenocarcinoma.
Results were correlated with clinicopathological parameters including age and histopathological grade or degree of differentiation.
Immune histochemical expression of CD10 was significantly increased in cases of benign prostatic hyperplasia comparing to cases of prostatic adenocarcinoma (P<0.001). The expression of CD10 in BPH was found to be significantly associated with young age clinical parameter (P<0.001). Also immune histochemical expression of CD10 was significantly increased by increasing Gleason score and grade group (P<0.001). The pattern of immune histochemical expression of CD10 was significantly changed from membranous to both membranous and cytoplasmic to cytoplasmic with increasing Gleason score and grade group (P<0.001).